Highlights in muscle relaxants

References

• Thomas KB. Curare: its History and Usage. Pitman Medical Publishing Co., Ltd, London, UK, 21–22 (1964).
   Google Scholar
• Bowman WC. Neuromuscular block. Br. J. Pharmacol.147(Suppl. 1), S277–S286 (2006).
   PubMed Web of Science ®Google Scholar
• West R. The action of curare on the respiratory mechanism. J. Physiol.91(4), 437–446 (1938).
   Google Scholar
• Bennet AE. Curare: a preventive of traumatic complications in convulsive shock therapy. Am. J. Psychiatr.97, 1040–1060 (1941).
   Google Scholar
• Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology3, 418–420 (1942).
   Google Scholar
• Viby-Morgensen J, Engbaek J, Eriksson I, Gramstad L, Jensen E, Koscielniak-Nielsen Z. Good clinical research practice (GCRP) in pharmacodynamics studies of neuromuscular blocking agents. Acta Aneaesthesiol. Scand.40, 59–74 (1996).
   Google Scholar
• Viby-Morgensen J, Ostergaard D, Donati F et al. Pharmacokinetics studies of neuromuscular blocking agents: good clinical research practice (GCRP). Acta Aneaesthesiol. Scand.44, 1169–1190 (2000).
   Google Scholar
• DeMonico HJ, Shah AS. Economic considerations in the use of neuromuscular blocking drugs. J. Clin. Anesth.6, 383–387 (1994).
   Google Scholar
• Armstrong DK, Crisp CB. Pharmacoeconomics issues of sedation, analgesia and neuromuscular blockade in critical care. New Horiz.2, 85–93 (1994).
   Google Scholar
• Meistelman C. Update on neuromuscular pharmacology. Curr. Opin. Anesthesiol.14, 399–404 (2001).
   Google Scholar
• Geldner G, Wulf H. Muscle relaxants suitable for day case surgery. Eur. J. Anaesthesiol.23, 43–46 (2001).
   Google Scholar
• Mertes PM, Laxenaire C. Allergic reactions occurring during anaesthesia. Eur. J. Anaesthesiol.19, 240–262 (2002).
   Web of Science ®Google Scholar
• Nguib M, Lien CA. Pharmacology of muscle relaxants and their antagonists. Miller’s Anesthesia Sixth Edition. Miller RD (Ed.). Elsevier Churchill Livingstone, NY, USA, 481–571 (2005).
   Google Scholar
• Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology69, 272–276 (1988).
   Google Scholar
• Wulf H, Kahl M, Ledowski T. Augmentation of neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane and i.v. anaesthesia. Br. J. Anaesth.80, 308–312 (1998).
   Google Scholar
• Wulf H, Ledowski T, Linstedt U, Proppe D, Sitzlack D. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anesthesia. Can. J. Anaesth.45, 526–532 (1998).
   Google Scholar
• De Lemons JM, Carr RR, Shalansky KF, Beven DR, Ronco JJ. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit. Care Med.27(12), 2648–2655 (1999).
   Google Scholar
• Dutta TK, Das AK, Sethuraman KR, Swaminathan RP. Neuroparalysis and ventilatory support in severe tetanus. J. Indian Med. Assoc.104(2), 63–66 (2006).
   Google Scholar
• Churchill-Davidson HC, Christie TH. The diagnosis of neuromuscular block in man. Br. J. Anaesth.31, 290–301 (1959).
   Google Scholar
• Viby-Mogensen J. Clinical Assessment of neuromuscular transmission Br. J. Anaesth.54, 209–223 (1982).
   PubMedGoogle Scholar
• Kopman AF. Measurement and monitoring of neuromuscular blockade. Curr. Opin. Anaesthesiol.15, 415–420 (2002).
   Google Scholar
• Eriksson LI, Sundman E, Olsson R et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans. Anesthesiology87, 1035–1043 (1997).
   PubMed Web of Science ®Google Scholar
• Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanism of pharyngeal and upper esophageal dysfunction in partially paralyzed humans. Anesthesiology92, 977–984 (2000).
   PubMed Web of Science ®Google Scholar
• Eriksson LI, Sato M, Severinghaus JW. Effects of vecuronium-induced partial neuromuscular block on hypoxic ventilatory responses. Anesthesiology78, 693–699 (1993).
   PubMed Web of Science ®Google Scholar
• Wyon N, Joensen H, Yamamoto Y, Lindahl SGE, Eriksson LI. Carotid body chemoreceptor function is impaired by vecuronium during hypoxia. Anesthesiology89, 1471–1479 (1999).
   Google Scholar
• Jonsson M, Kim C, Yamamoto Y, Runold MK, Lindahl SGE, Eriksson LI. Atracurium and vecuronium block nicotine-induced carotid body responses. Acta Anaesthesiol. Scand.94, 117–122 (2002).
   Google Scholar
• Kopman AF, Yee PS, Neumann GG. Relationship of the train-of-four fade to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology86, 765–771 (1997).
   PubMed Web of Science ®Google Scholar
• Eriksson LI. Evidence-based practice and neuromuscular monitoring: it’s time for routine quantitative assessment. Anesthesiology98(5), 1037–1039 (2003).
   PubMed Web of Science ®Google Scholar
• Hunter JM. Adverse effects of neuromuscular blocking drugs. Br. J. Anaesth.59, 46–60 (1987).
   Google Scholar
• Martyn J, Durieux ME. Succinylcholine: new insights into mechanisms of action of an old drug. Anesthesiology104(4), 633–634 (2006).
   Google Scholar
• Mrtyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology104(1), 158–169 (2006).
   Google Scholar
• Hou VY, Hirshman CA, Emala CW. Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology88(3), 744–750 (1998).
   Google Scholar
• Jooste E, Klafter F, Hirshman CA, Emala CW. A mechanism for rapacurium-induced bronchospasm: M2 muscarinic receptor antagonism. Anesthesiology98(4), 906–911 (2003).
   Google Scholar
• Khuenl-Brady KS, Sparr H. Clinical pharmacokinetetics of rocuronium bromide. Clin. Pharmacokinet.31, 174–183 (1996).
   PubMed Web of Science ®Google Scholar
• Hill SA, Scott RPF, Savarese JJ. Structure-activity relationships: from tubocurarine to the present day. Baillieres Clin. Anaesthesiol.8, 317–348 (1994).
   Google Scholar
• Sanders KA, Aucker R. Early recognition of risk factors for persistent effects of vecuronium. South. Med. J.89, 411–414 (1996).
   Google Scholar
• Stenlake JB, Waigh RD, Dewar GH. Biodegradable neuromuscular blocking agents. 6 Stereochemical studies on atracurium and related polyalkylene di-esters. Eur. J. Med. Chem.19, 441–450 (1984).
   Google Scholar
• Fodale V, Sanamaria LB. Laudanosine, an atracurium and cisatracurium metabolite. Eur. J. Anaesthesiol.19, 466–473 (2002).
   PubMed Web of Science ®Google Scholar
• Kisor DF, Schmith VD. Clinical pharmacokinetetics of cisatracurium besilate. Clin. Pharmacokinet.36, 27–40 (1999).
   PubMed Web of Science ®Google Scholar
• Savarese JJ, Mogensen J, Reich D et al. The haemodynamic profile of cis-atracurium. Curr. Opin. Anesthesiol.9, S36–S41 (1996).
   Google Scholar
• Lien CA, Belmont MR, Abalos A et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology82, 1131–1138 (1995).
   Google Scholar
• Savarese JJ, Ali HH, Basta SJ et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW 1090U), a short acting non-depolarizing ester neuromuscular blocking drug. Anesthesiology68, 723–732 (1988).
   PubMedGoogle Scholar
• Head-Rapson AG, Devlin JC, Parker CJ, Parker CJ, Hunter JM. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br. J. Anaesth.73, 613–618 (1994).
   PubMed Web of Science ®Google Scholar
• Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology84, 300–308 (1996).
   Google Scholar
• Boros EE, Samano V, Ray JA et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J. Med. Chem.46, 2502–2515 (2003).
   Google Scholar
• Belmont MR, Lien CA, Tjan J et al. Clinical pharmacology of GW280430A in humans. Anesthesiology100, 768–773 (2004).
   PubMed Web of Science ®Google Scholar
• Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ. Allergic reactions occurring during anesthesia: diagnostic approach. Acta Clin. Belg.59(1), 34–43 (2004).
   PubMed Web of Science ®Google Scholar
• Mertes PM, Laxenaire MC. Adverse reactions to neuromuscular blocking agents. Curr. Allergy Asthma Rep.4(1), 7–14 (2004).
   PubMed Web of Science ®Google Scholar
• Mertes PM, Laxenaire MC. Allergy and anaphylaxis in anaesthesia. Minerva Anestsiol.70, 285–291 (2004).
   PubMedGoogle Scholar
• Toh KW, Deacock SJ, Fawcett WJ. Severe anaphylactic reaction to cisatracurium. Anesth. Analg.88, 462–464 (1999).
   Google Scholar
• Mertes PM, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999–2000. Anesthesiology99(3), 536–545 (2003).
   PubMed Web of Science ®Google Scholar
• Ording H. Incidence of malignant hyperthermia in Denmark. Anesth. Analg.64, 700–704 (1985).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth. Analg.98, 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after single intubating dose of nondepolarizing muscle relaxants with an intermediate duration of action. Anesthesiology98(5), 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anaesthesiol.72(3), 97–109 (2006).
   PubMed Web of Science ®Google Scholar
• Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth. Analg.80, 1168–1174 (1995).
   Google Scholar
• Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology104, 631–633 (2006).
   Google Scholar
• Gijsenberg F, Ramael S, Houwing N, Van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology103, 695–703 (2005).
   Google Scholar
• Sorgenfrei IF, Norrild K, Larsen PB et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology104, 667–674 (2006).
   PubMed Web of Science ®Google Scholar
• de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology104(4), 718–723 (2006).
   Google Scholar
• Andrews JL, Kumar N, van den Brom RH, Olkkola KT, Roest GJ, Wright PM. A large sample randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anesthesia along with propofol. Acta Anaesthesiol. Scand.43, 4–8 (1999).
   Web of Science ®Google Scholar
• Scwarz S, Ilias W, Lackner F, Mayrhofer O, Foldes FF. Rapid tracheal intubation with vecuronium: the priming principle. Anesthesiology62, 388–391 (1985).
   Google Scholar
• Kopman AF, Khan NA, Neuman GG. Precurarization and priming: a theoretical analysis of safety and timing. Anesth. Analg.93, 1253–1256 (2001).
   Google Scholar
• Leykin Y, Pellis T, Lucca M, Gullo A. Effects of ephedrine on intubating conditions following priming with rocuronium. Acta Anesthesiol. Scand.49, 792–797 (2005).
   Google Scholar
• Leykin Y, Pellis T, Lucca M, Gullo A. Intubation conditions following rocuronium: influence of induction agent and priming. Anaesth. Intensive Care33, 462–468 (2005).
   Google Scholar
• Meretjo OA. Neuromuscular blocking agents in paediatric patients: influence of age on the response. Anaesth. Intensive Care18, 440–448 (1990).
   Google Scholar
• Lemmens HJM, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth. Analg.102, 438–442 (2006).
   PubMed Web of Science ®Google Scholar
• Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth. Analg.99, 1090–1094 (2004).
   PubMed Web of Science ®Google Scholar
• Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth. Analg.99, 1086–1089 (2004).
   PubMed Web of Science ®Google Scholar
• Gora-Harper ML, Hessel E 2nd, Shadick D. Effect of prescribing guidelines on the use of neuromuscular blocking agents. Am. J. Health Syst. Pharm.52(17), 1900–1904 (1995).
   Google Scholar
• Savarese JJ, Miller RD, Lien CA, Caldwell JE. Pharmacology of muscle relaxants and their antagonists. In: Anesthesia Fifth Edition. RD Miller (Ed.). Churchill and Livingstone, NY, USA (2000).
   Google Scholar